- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne - - Dermata recently completed enrollment in its DMT310 Phase 3 STAR-1 ...
Retinol is renowned for its skincare benefits, but its initial use can sometimes lead to purging. Here’s how to recognise and manage this phase for healthier skin.
STAR-1 topline results expected in March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year - - Phase 2b for DMT310 achieved statistically significant r ...